+

WO2013012007A1 - Composition d'agent anti-virus - Google Patents

Composition d'agent anti-virus Download PDF

Info

Publication number
WO2013012007A1
WO2013012007A1 PCT/JP2012/068213 JP2012068213W WO2013012007A1 WO 2013012007 A1 WO2013012007 A1 WO 2013012007A1 JP 2012068213 W JP2012068213 W JP 2012068213W WO 2013012007 A1 WO2013012007 A1 WO 2013012007A1
Authority
WO
WIPO (PCT)
Prior art keywords
vol
virus
salts
quaternary ammonium
chloride
Prior art date
Application number
PCT/JP2012/068213
Other languages
English (en)
Japanese (ja)
Inventor
惇 佐藤
浩美 久保田
剛久 矢野
佳子 宮原
Original Assignee
花王株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 花王株式会社 filed Critical 花王株式会社
Publication of WO2013012007A1 publication Critical patent/WO2013012007A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an antiviral composition having a virus inactivating effect.
  • Viral infectious diseases such as influenza and colds are considered to be one of the important preventive measures to clean fingers and the environment.
  • viral acute gastroenteritis and diarrhea are not only confirmed as outbreaks in nursing homes, schools, hospitals, etc., but also outbreaks due to food poisoning through contaminated food in restaurants, cooking facilities, etc.
  • These causative viruses include non-enveloped viruses such as norovirus, sapovirus, and rotavirus, and infection of children and the elderly may cause serious symptoms.
  • hand-foot-and-mouth disease which is a typical pediatric infection
  • foot-and-mouth disease-causing viruses that cause tremendous damage to livestock are also classified as non-enveloped viruses. is there.
  • norovirus has been detected not only in Japan but around the world as a causative virus for non-bacterial food poisoning and acute gastroenteritis.
  • bacteria such as Staphylococcus aureus and Bacillus cereus have been conventionally known.
  • food poisoning caused by norovirus causing acute gastroenteritis is about 25% of the number of food poisoning cases, and the number of patients is about about the whole. It accounts for half, is the largest, and is regarded as a problem as a virus that causes mass infection.
  • the infection route is well-known for oral infection caused by eating shellfish such as raw oysters.
  • Norovirus is an RNA virus that does not have an envelope (membrane-like structure) classified in the Caliciviridae and Norovirus genus, has a strong resistance to acid (gastric acid), and a small amount (about 10 to 100). It is known to be infected with. At present, there are no vaccines or treatments for norovirus, and the only treatment is to prevent norovirus infection by eliminating viruses or inactivating the virus by cleaning or disinfecting food, cooking utensils, and fingers that may cause it. Is the law. However, since norovirus has strong physicochemical resistance, ethanol and disinfectants including cationic surfactants that are effective against many bacteria are effective against norovirus in general usage. You may not get.
  • disinfectants such as chlorine bleach (sodium hypochlorite, etc.), iodine agents (povidone iodine, etc.), aldehyde agents (glutaral, etc.) and peracetic acid preparations are used for inactivating norovirus.
  • disinfectants are highly irritating to humans and corrode metals.
  • chlorine-based bleaching agent has the effect of bleaching the color pattern of the fiber, and there is a limit in use for textile products and clothing. For this reason, in consideration of the safety of the user, the object to be used, and the usage scene, there are limitations on using these drugs in living environments, fingers, cooking utensils, clothing, and the like.
  • a composition containing a lower alcohol, an alkaline substance and a cationic surfactant (Patent Document 1) , A composition containing hydrogen peroxide, benzyl alcohol and a silver component (Patent Document 2), a composition containing a specific amine and / or a quaternary ammonium salt and a specific alkanolamine (Patent Document 3), A composition having a quaternary ammonium salt as an active ingredient and a pH of 5 to 9 (Patent Document 4) or a composition containing a plant extract containing a natural product tannin as an active ingredient (Patent Document 5) has been reported. Yes.
  • the present invention relates to the following 1) to 5).
  • a method for enhancing the activation effect (A) Combined with the quaternary ammonium salt of (A) above to enhance the virus inactivating effect of one or more quaternary ammonium salts selected from dialkyldimethylammonium salts and alkylbenzyldimethylammonium salts (B) Use of benzyl alcohol.
  • the present invention relates to providing an antiviral composition which has little irritation and corrosivity and has a virus inactivating effect, particularly an excellent inactivating effect against non-enveloped viruses such as Norovirus.
  • the present inventors have examined components effective for preventing infection of non-enveloped viruses such as Norovirus. When a specific quaternary ammonium salt and benzyl alcohol are used in combination, the quaternary ammonium salt is used. It was found that the virus inactivating effect was greatly increased as compared with the case of using alone, and it was useful as an antiviral composition.
  • the composition of the present invention has an excellent antiviral action against non-enveloped viruses such as Norovirus, and is less irritating and corrosive, so that it can be used safely and for a short time.
  • non-enveloped viruses such as Norovirus
  • it is possible to inactivate the virus attached to floors and walls of large-scale cooking facilities, kitchen spaces, etc., medical equipment, food processing equipment, cooking utensils and the like.
  • it can be effectively used to inactivate viruses and disinfect hands and fingers attached to floors, walls, furniture, and the like in the dwellings of ordinary households.
  • Dialkyldimethylammonium salt and alkylbenzyldimethylammonium salt which are quaternary ammonium salts of component (A), are known compounds as antibacterial cationic surfactants. These may be used alone or in combination of two or more.
  • the dialkyldimethylammonium salt and the alkylbenzyldimethylammonium salt preferably include a dialkyl (C 8-18 ) dimethylammonium salt and an alkyl (C 12-16 ) benzyldimethylammonium salt, respectively.
  • the alkyl group in the dialkyldimethylammonium salt includes an alkyl group having 8 to 18 carbon atoms, preferably a linear alkyl group having 8 to 18 carbon atoms.
  • Specific examples include octyl, decyl, dodecyl (lauryl), tetradecyl (myristyl), hexadecyl (cetyl), heptadecyl, octadecyl (stearyl), and more preferably octyl, decyl, and dodecyl.
  • the alkyl group in the alkylbenzyldimethylammonium salt includes an alkyl group having 12 to 16 carbon atoms, preferably a linear alkyl group having 12 to 16 carbon atoms. Specific examples include dodecyl (lauryl), tetradecyl (myristyl), and hexadecyl (cetyl).
  • Suitable dialkyldimethylammonium salts include didecyldimethylammonium salts, and alkylbenzyldimethylammonium salts include dodecylbenzyldimethylammonium salts, tetradecylbenzyldimethylammonium salts, and hexadecylbenzyldimethylammonium salts.
  • Ammonium salts include salts with halide ions such as F ⁇ , Cl ⁇ , Br ⁇ and I ⁇ , NO 3 ⁇ , SO 4 2 ⁇ , etc., and salts with halide ions are preferred and chlorides. More preferred are salts with ions.
  • More preferable quaternary ammonium salts include dodecylbenzyldimethylammonium chloride, tetradecylbenzyldimethylammonium chloride, hexadecylbenzyldimethylammonium chloride, and didecyldimethylammonium chloride.
  • the quaternary ammonium salt of the present invention can be produced by a known method, and a commercially available product can also be used.
  • Cotamin D10P manufactured by Kao Corporation
  • Sanizol 08 manufactured by Kao Corporation
  • Sanisole C manufactured by Kao Corporation
  • the quaternary ammonium salt alone has an inactivating effect against norovirus (by an alternative experiment with feline calicivirus (FCV)) at a contact time of about 60 minutes alone, but the effect is insufficient in a short time. There is no significant inactivation effect unless used for a long time or at a high concentration.
  • the component (B) benzyl alcohol can be used by purchasing a commercial product.
  • a commercial product For example, products from Kanto Chemical Co., Inc. or Tokyo Chemical Industry Co., Ltd. can be purchased and used.
  • other organic solvents can be mixed and used with benzyl alcohol as long as the antiviral effect is not affected.
  • composition of the present invention containing the above (A) quaternary ammonium salt and (B) benzyl alcohol, the antiviral activity of the quaternary ammonium salt against norovirus (by an alternative experiment with feline calicivirus (FCV)) is remarkably increased.
  • FCV feline calicivirus
  • composition of the present invention may be any composition that exhibits a virus inactivation effect that removes or significantly reduces the ability to infect or proliferate viruses, and may denature or disrupt virus particles and nucleic acids (RNA). As a result, it may be possible to reduce or inhibit the ability of the virus to infect or proliferate by adsorption to the surface of the virus or host cell, binding of the virus with an enzyme, or the like.
  • RNA nucleic acids
  • the “virus” is preferably a non-enveloped virus, that is, a single-stranded (+) RNA virus having no envelope, a single-stranded ( ⁇ ) RNA virus, a double-stranded RNA virus, a single-stranded virus.
  • a non-enveloped virus that is, a single-stranded (+) RNA virus having no envelope, a single-stranded ( ⁇ ) RNA virus, a double-stranded RNA virus, a single-stranded virus.
  • viruses include DNA viruses and double-stranded DNA viruses. Examples of such viruses include viruses belonging to the Caliciviridae, Picornaviridae, Parvoviridae, Papillomaviridae, Polyomaviridae, and Adenoviridae families.
  • the composition of the present invention is excellent in inactivating effect against Caliciviridae virus (single-stranded (+) virus), and among the Caliciviridae viruses, the genera Besivirus, Norovirus and Sapovirus It has an excellent inactivation effect on viruses belonging to the group, and in particular has an excellent inactivation effect on viruses belonging to the genus Besivirus and Norovirus.
  • the mass ratio of the components (A) and (B) is such that (A) / (B) is 3/1 to 1/500, more preferably 3/1 to 1/40, and further 2/1 to 1/10 is preferable.
  • composition of the present invention comprises only other components (A) and (B) or, if necessary, other components such as a chelating agent in order to further improve the antiviral activity and maintain the effect.
  • a chelating agent in order to further improve the antiviral activity and maintain the effect.
  • products and preparations used for cleaning of floors and walls of large-scale cooking facilities, kitchen spaces, medical equipment, food processing equipment, cooking utensils, and various living environments Providing antiviral activity to products and preparations used in foods (eg kitchen detergents, faucet care agents, bath detergents, toilet cleaners, floor and furniture cleaning products, etc.) and clothes and textile products Can be used as a material for.
  • the chelating agent (1) tripolyphosphoric acid, pyrophosphoric acid, orthophosphoric acid, hexametaphosphoric acid and alkali metal salts thereof, (2) ethylenediaminetetraacetic acid, hydroxyiminodiacetic acid, dihydroxyethylglycine, nitrilotriacetic acid, hydroxyethylenediamine Triacetic acid, diethylenetriaminepentaacetic acid, triethylenetetraminehexaacetic acid and alkali metal salts or alkaline earth metal salts thereof, (3) aminotrimethylenephosphonic acid, 1-hydroxyethylidene-1,1-diphosphonic acid, ethylenediaminetetramethylenephosphone Acid, diethylenetriaminepentamethylenephosphonic acid, N-oxide of aminotrimethylenephosphonic acid and alkali metal salts or alkaline earth metal salts thereof, (4) acrylic acid and methacrylic acid?
  • composition of the present invention may further contain, for example, additives such as oil, higher fatty acids, silicones, pH adjusters, thickeners, suspending agents, powder components, natural extracts, pigments, and fragrances as appropriate. It can be used to produce an antiviral composition that is blended and stirred and dispersed or dissolved.
  • additives such as oil, higher fatty acids, silicones, pH adjusters, thickeners, suspending agents, powder components, natural extracts, pigments, and fragrances as appropriate. It can be used to produce an antiviral composition that is blended and stirred and dispersed or dissolved.
  • acid agents such as inorganic acids such as hydrochloric acid and sulfuric acid, organic acids such as citric acid, succinic acid, malic acid, fumaric acid, tartaric acid, malonic acid, maleic acid, sodium hydroxide and water
  • Alkaline agents such as sodium carbonate and potassium carbonate such as potassium oxide, ammonia and derivatives thereof, amine salts such as monoethanolamine, diethanolamine, and triethanolamine may be used alone or in combination.
  • these acid agents and alkali agents may be used in combination as a buffer system.
  • the above composition is preferably adjusted to have a pH of 2 to 12 at 20 ° C. with the above pH adjuster, and particularly to have a pH of 4 to 11 in terms of effects on humans and substrates. To preferred.
  • the content of the quaternary ammonium salt of the component (A) in the composition of the present invention is 0.05 vol% or more and 0.5 vol% or less, more preferably 0.1 vol% or more from the viewpoint of antiviral activity. More preferably, it is 0.2 vol% or more, and 0.5 vol% or less, 0.2 vol% or less, or 0.1 vol% or less is mentioned from the viewpoint of blending into a product or the like. For example, 0.05 to 0.5 vol%, 0.1 to 0.5 vol%, 0.2 to 0.5 vol%, 0.05 to 0.2 vol%, 0.05 to 0.1 vol%, 0.1 to 0.2 vol% etc. are mentioned.
  • the content of benzyl alcohol as component (B) is 0.5 to 2 vol%, but from the viewpoint of antiviral activity, it is more preferably 1 vol% or more, and even more preferably 1.5 vol% or more. From the viewpoint of property and blending, 2 vol% or less, 1.5 vol% or less, or 1.0 vol% or less can be mentioned. Examples thereof include 0.5 to 2 vol%, 0.5 to 1 vol%, 0.5 to 1.5 vol%, and 1 to 2 vol%.
  • the composition of the present invention is a place where there is a risk of virus attachment, for example, kitchen (kitchen floor, kitchen space such as walls), sink, refrigerator, etc.
  • Tableware such as dishes, refrigerators, toilets, baths, toilets, living rooms such as living rooms and bedrooms, textile products such as sofas, cushions, bedding and curtains can be used by contacting them.
  • the contact is not particularly limited, and examples include direct application of the composition to the target surface, filling in a spraying device such as a trigger or aerosol, and spraying.
  • composition of this invention contact there is no restriction
  • it can be liquid, gel, or paste.
  • a liquid it can be used as a spray, lotion or the like.
  • a known spray container such as a trigger spray container (direct pressure or pressure accumulation type) or a dispenser type pump spray container can be filled, and the spray amount can be adjusted to spray the virus in a place where it is or is thought to exist. And so on.
  • the composition of the present invention solubilized on a base material comprising a natural fiber, a regenerated fiber such as rayon, a synthetic fiber such as polyethylene, polypropylene, polyester, or a woven or non-woven web of a mixture of natural fiber and synthetic fiber It can be used by containing a carrier and various additives as required. Specifically, it can be used for sterilization of skin conditioners, pet care products, surfaces of household kitchens and bathrooms, surfaces of exercise equipment, and the like.
  • the composition of the present invention can be used by kneading it with a resin.
  • resins that can be kneaded include natural, petroleum, synthetic waxes, rosin resins, ethylene-vinyl acetate copolymers, ethylene-vinyl alcohol copolymers, polyesters, polyolefins, acrylic resins, etc. Is mentioned.
  • the kneaded material can be used as it is, or can be supported on a porous carrier, formed into a sheet, or used as a laminate.
  • porous carrier examples include a natural polymer such as cellulose and chitosan, the above synthetic resin, an inorganic porous material such as calcium silicate, and the like in an arbitrary shape such as a granular shape and a sheet shape.
  • the above-mentioned kneaded product or laminate can be used, for example, by installing it in an air conditioner, toilet, bathroom, living room, hospital room, hospital waiting room, dust box, etc. and gradually evaporating the antiviral composition.
  • An antiviral composition containing the following components (A) and (B).
  • A One or more quaternary ammonium salts selected from dialkyldimethylammonium salts and alkylbenzyldimethylammonium salts 0.05 vol% to 0.5 vol%
  • B benzyl alcohol 0.5 vol% to 2 vol% ⁇ 5 >
  • A One or more quaternary ammonium salts selected from dialkyldimethylammonium salts and alkylbenzyldimethylammonium salts, and (B) benzyl alcohol is used in combination with the quaternary ammonium salt virus.
  • the component (A) is more preferably 0.1 vol% or more, more preferably 0.2 vol% or more, and 0.5% or less, 0.2 vol%. Hereinafter, it is 0.1 vol% or less.
  • the component (B) is more preferably 1 vol% or more, more preferably 1.5 vol% or more, and 2 vol% or less, 1.5 vol% or less, or 1 0.0 vol% or less.
  • the mass ratio of the components (A) and (B) is preferably (A) / (B) of 3/1 to 1/500, more preferably Is 3/1 to 1/40, more preferably 2/1 to 1/10.
  • the quaternary ammonium salt (A) is preferably one or more selected from octylbenzyldimethylammonium chloride, dodecylbenzyldimethylammonium chloride and didecyldimethylammonium chloride. It is. ⁇ 11> In the above ⁇ 1> to ⁇ 9>, the virus to be suitably applied is a non-enveloped virus. ⁇ 12> In the above items ⁇ 1> to ⁇ 9>, a virus that is preferably applied is a virus belonging to the genus Norovirus.
  • Example 1 Preparation of antiviral agent
  • alkylbenzyldimethylammonium chloride Sanisol C (manufactured by Kao)
  • linear alkyl mixture of 12 to 16 carbon atoms
  • benzyldimethylammonium chloride and di Decyldimethylammonium chloride (manufactured by Kao)
  • BA, (WAKO) benzyl alcohol
  • Feline calicivirus F-9 ATCC VR-782 (feline calicivirus (FCV)) was used as the test virus. Since norovirus culture systems have not been established, feline calicivirus classified into the same caliciviridae from morphology and genetic information is used as an alternative virus for norovirus, and a method for confirming virus infectivity is common. (Journal of Hospital Infection, 41, p51-57, 1999). The cells used were CRFK (Crandell Rees feline kidney) cells (Dainippon Sumitomo Pharma Co., Ltd.).
  • the medium used was a cell growth medium prepared by adding 10% fetal calf serum to Eagle MEM “Nissui” (1) (Nissui Pharmaceutical).
  • Eagle MEM “Nissui” (1) As the cell maintenance medium, Eagle MEM “Nissui” (1) to which 2% fetal calf serum was added was used.
  • CRFK cells were monolayer cultured in tissue culture flasks using cell growth media. After monolayer culture, the cell growth medium was removed from the flask and inoculated with the test virus. Next, cell maintenance medium was added and cultured in a carbon dioxide incubator (CO 2 concentration: 5%) at 37 ° C. ⁇ 1 ° C. for 1 to 5 days. After culturing, cell morphology was observed using an inverted phase contrast microscope to confirm that cytopathic effect (CPE) occurred. Next, the culture solution was centrifuged (3,000 rpm, 10 minutes), and the resulting supernatant was used as a virus suspension.
  • CO 2 concentration CO 2 concentration: 5%
  • Virus inactivation test 0.1 ml of the virus suspension was added to 1 ml of each specimen shown in Tables 1 to 3 and mixed to obtain a working solution. Acting at room temperature, test 1 was diluted with cell maintenance medium after 5, 10, 20 and 30 minutes. Test 2 was similarly diluted after 0.5, 1 and 5 minutes. However, dilution was performed at a dilution concentration confirmed by a preliminary test. In addition, it tested similarly using purified water as a control, and measured the virus infectious titer at the start.
  • didecyldimethylammonium chloride alone (0.05%) reduces the infectious value only by 2.4 log TCID 50 in 5 minutes
  • didecyldimethylammonium chloride (0.05%) contains 0.5% BA.
  • 5% was added, a decrease of 4log TCID 50 was confirmed in 0.5 minutes when 2% BA was added (Table 3). From this, it was shown that the high FCV inactivation effect (norovirus inactivation effect) can be exhibited in a short time by using the cationic surfactant of the present invention and BA together.
  • Example 2 (1) Preparation of test solution Alkylbenzyldimethylammonium chloride (Sanisol C (manufactured by Kao), linear alkyl (mixture of 12 to 16 carbon atoms) benzyldimethylammonium chloride) and didecyl as the quaternary ammonium salt of (a) Dimethylammonium chloride (DDAC; manufactured by Kao) was used as benzyl alcohol (BA, (WAKO)) as (b).
  • DDAC Dimethylammonium chloride
  • BA benzyl alcohol
  • Novirus virus-like particles NoV VLPs Shape test method NoV VLPs are expressed and purified in large quantities of capsid proteins that compose norovirus. I'm taking it.
  • NoV VLPs were produced using a recombinant protein mass expression system using baculovirus according to the method of Hansman, G. S. et al. (Non-patent Document 1). That is, the gene region encoding the structural protein (accession No.
  • SM-2 Bio-beads suspension 50% w / v dispensed in a microtube, stirred for 2 minutes, and then 10 ⁇ L of the supernatant was subjected to TEM observation.
  • SM-2 bio beads were suspended in 10 mM HEPES so as to be 50 (w / v)% and autoclaved.
  • the NoV VLPs after the contact test were used for TEM (Transmission Electron Microscope) observation, and the anti-norovirus effect of each test solution was predicted by capturing changes in the particle structure.
  • FIG. 1 shows a TEM photograph when Sanisole C (0.05%) and BA (2.00%) were added for 0.5 minutes. From FIG. 1, it was confirmed that the particle structure of Norovirus virus like particles (NoV VLPs) composed only of norovirus structural proteins was deformed by the combined action of alkylbenzyldimethylammonium salt and benzyl alcohol. .
  • NoV VLPs Norovirus virus like particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition d'agent anti-virus présentant de faibles niveaux d'irritation et de corrosivité ainsi qu'un excellent effet d'inactivation des virus, en particulier un excellent effet d'inactivation de virus non enveloppés, tels qu'un norovirus. Une composition d'agent anti-virus comprend les composants (A) et (B) suivants : (A) 0,05 à 0,5% en volume incluant au moins un sel d'ammonium quaternaire sélectionné dans le groupe constitué par un sel de dialkyldiméthylammonium et un sel d'alkylbenzyldiméthylammonium, et (B) 0,5 à 2% en volume incluant un alcool de benzyle.
PCT/JP2012/068213 2011-07-20 2012-07-18 Composition d'agent anti-virus WO2013012007A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-159153 2011-07-20
JP2011159153 2011-07-20

Publications (1)

Publication Number Publication Date
WO2013012007A1 true WO2013012007A1 (fr) 2013-01-24

Family

ID=47558184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/068213 WO2013012007A1 (fr) 2011-07-20 2012-07-18 Composition d'agent anti-virus

Country Status (2)

Country Link
JP (1) JP2013040167A (fr)
WO (1) WO2013012007A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111455655A (zh) * 2020-04-24 2020-07-28 广东溢达纺织有限公司 一种抗病毒面料及其制备方法
WO2020210789A1 (fr) * 2019-04-12 2020-10-15 Ecolab Usa Inc. Solution de nettoyage de surface dure avec activité viricide rapide
CN112546034A (zh) * 2020-12-18 2021-03-26 上海海禾医疗科技有限公司 一种灭活病毒免洗泡沫型消毒剂
CN112618525A (zh) * 2020-12-18 2021-04-09 上海海禾医疗科技有限公司 一种快速灭活冠状病毒的消毒液

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6444104B2 (ja) * 2014-09-17 2018-12-26 シーバイエス株式会社 洗濯用液体殺菌洗浄剤組成物およびそれを用いた繊維品の非エンベロープウイルスの不活化方法
JP6574119B2 (ja) * 2015-08-31 2019-09-11 大王製紙株式会社 ノロウイルス不活化評価方法
WO2020022437A1 (fr) * 2018-07-27 2020-01-30 富士フイルム株式会社 Composition antivirale, composition anti-norovirus, pulvérisateur, chiffon et composé
WO2023145619A1 (fr) * 2022-01-31 2023-08-03 花王株式会社 Composition d'inactivation de virus non enveloppé

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03163007A (ja) * 1989-08-22 1991-07-15 Eastman Kodak Co 抗微生物組成物
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
WO2011002929A1 (fr) * 2009-06-30 2011-01-06 The Trustees Of Columbia University In The City Of New York Compositions antimicrobiennes/de conservation comprenant des agents botaniques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03163007A (ja) * 1989-08-22 1991-07-15 Eastman Kodak Co 抗微生物組成物
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
WO2011002929A1 (fr) * 2009-06-30 2011-01-06 The Trustees Of Columbia University In The City Of New York Compositions antimicrobiennes/de conservation comprenant des agents botaniques

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210789A1 (fr) * 2019-04-12 2020-10-15 Ecolab Usa Inc. Solution de nettoyage de surface dure avec activité viricide rapide
AU2020271558B2 (en) * 2019-04-12 2023-03-02 Ecolab Usa Inc. Hard surface cleaning solution with rapid viricidal activity
CN111455655A (zh) * 2020-04-24 2020-07-28 广东溢达纺织有限公司 一种抗病毒面料及其制备方法
CN112546034A (zh) * 2020-12-18 2021-03-26 上海海禾医疗科技有限公司 一种灭活病毒免洗泡沫型消毒剂
CN112618525A (zh) * 2020-12-18 2021-04-09 上海海禾医疗科技有限公司 一种快速灭活冠状病毒的消毒液

Also Published As

Publication number Publication date
JP2013040167A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
WO2013012007A1 (fr) Composition d'agent anti-virus
KR20110103443A (ko) 규소함유 화합물을 포함하는 항균제 조성물 및 항바이러스 조성물, 및 항균화 방법, 세정 및 구강세정 방법, 항균제 및 항바이러스제 고정화 방법
JP6444104B2 (ja) 洗濯用液体殺菌洗浄剤組成物およびそれを用いた繊維品の非エンベロープウイルスの不活化方法
JP2017105723A (ja) カリシウイルス不活化効果を有する組成物
JP2019052107A (ja) 殺菌・ウイルス不活化剤及び殺菌・ウイルス不活化方法
JP2010053091A (ja) 非エンベロープ型ウイルスの不活化剤
JP2013014551A (ja) ウイルス不活化組成物
JP7421902B2 (ja) ウイルス不活性化剤組成物
JP2017008443A (ja) 繊維製品用抗ウイルス組成物
JP2020033279A (ja) 抗ノロウイルス剤、消毒剤及び洗浄剤
JPWO2014115860A1 (ja) 殺ウイルス剤
JP7220449B2 (ja) 殺菌・ウイルス不活化剤及び殺菌・ウイルス不活化方法
JP6795720B1 (ja) コロナウイルス不活化剤
JP2022026763A (ja) ウイルス不活性化剤組成物
JP2021066699A (ja) ウイルス不活性化剤組成物
JP7610364B2 (ja) ノロウイルス不活化剤
JP7340290B2 (ja) 抗エンベロープウイルス中性洗浄剤、消毒剤組成物、及びエンベロープウイルスの不活性化方法
JP7421903B2 (ja) ウイルス不活性化剤組成物
WO2022239605A1 (fr) Agent virucide
JP2022001555A (ja) ヒトノロウイルス不活化剤
JP6936536B1 (ja) 殺菌・ウイルス不活性化組成物
WO2022009352A1 (fr) Agent d'inactivation du coronavirus
JP2016141673A (ja) ウイルス不活化のための液体組成物
WO2022085710A1 (fr) Agent d'inactivation de coronavirus
CN118890962A (zh) 病毒或菌的灭活方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815525

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12815525

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载